* Bioventus Inc BVS.OQ BVS.O is expected to show a fall
in
quarterly revenue when it reports results on May 11.
* The Durham North Carolina-based company is expected to
report
a 0.6% decrease in revenue to $116.582 million from $117.29
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. The company's guidance on
March 31 2023, for the period ended March 31, was for revenue
between $118.46 million and $120.81 million.
* Refinitiv's mean analyst estimate for Bioventus Inc is
for a
loss of 15 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$4, above its last closing price of $0.93.
The company's guidance on March 31 2023 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD118.46 million and USD7.18
million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.05 0.05 -0.06 Missed -226.3
Sep. 30 2022 0.12 0.12 0.08 Missed -34.4
Jun. 30 2022 0.15 0.16 0.10 Missed -35.9
Mar. 31 2022 0.05 0.05 0.04 Missed -16.7
Dec. 0.17 0.18 0.26 Beat 46.5
31 2021
Sep. 30 2021 0.14 0.14 0.25 Beat 78.6
Jun. 30 2021 0.10 0.14 0.16 Beat 16.4
Mar. 31 2021 0.10 0.10 0.15 Beat 57.9
This summary was machine generated May 5 at 18:35 GMT. All
figures in US dollars unless otherwise stated